The rate of acquisition of genomic changes in cancer has been the topic of much discussion, with several recent investigations finding evidence of punctuated evolution instead of gradual accumulation ...

The UK Health Security Agency (UKHSA) has issued advice to anyone with symptoms of Covid as cases of the latest variants ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

All-in-one migraine supplements can be a convenient way to streamline your migraine prevention routine. Learn about key ingredients, potential side effects, and how to choose the right option for your ...

The $14 million facility in New Hyde Park will focus on both breast and gynecological cancers, officials said.

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

APLS is expanding SYFOVRE's potential with a phase 2 study combining it with siRNA APLS-3007, aiming to enhance efficacy in ...

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...

Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...